IPA/TESA Blend 15mg
IPA/TESA Dual GH Secretagogue Stack for Research
Pre-blended 5mg Ipamorelin + 10mg Tesamorelin for synergistic GH secretagogue research combining GHRP and GHRH mechanisms.
IPA/TESA Dual GH Secretagogue Stack for Research
IPA/TESA blend variant combining Ipamorelin ghrelin receptor agonism with Tesamorelin GHRH receptor activation for amplified GH and IGF-1 research.
As one of the most studied compounds in the bundles & stacks research space, IPA/TESA has attracted sustained scientific interest across GH secretagogue research, Combined GHRP+GHRH studies. Peer-reviewed evidence indicates that dual GH secretagogue combination, which has positioned IPA/TESA as a reference standard for researchers exploring gh secretagogue research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
IPA/TESA Documented Benefits: 1 Documented Mechanisms
Synergistic GH Release
Complementary GHRP+GHRH mechanism for amplified GH secretion.
How IPA/TESA Works: Molecular Mechanism & Pathway
Ipamorelin GHS-R1a + Tesamorelin GHRH-R dual activation for synergistic GH secretion.
The 1 primary research pathways identified for IPA/TESA — Synergistic GH Release — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that convenient pre-blended format, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, IPA/TESA's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
IPA/TESA is routinely studied alongside Tesamorelin and Ipa/CJC Blend in bundles & stacks-focused compound panels. Researchers investigating gh secretagogue research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 99%+ purity has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All IPA/TESA research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Dual GH secretagogue combination
- Convenient pre-blended format
- 99%+ purity
Ideal For
- GH secretagogue research
- Combined GHRP+GHRH studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on IPA/TESA. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Dual GH secretagogue combination
Convenient pre-blended format
99%+ purity
Third-Party Verified Every Batch
Each vial of IPA/TESA is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
